natgillin/translations-raw huggingface dataset:
Den ene side af tabletten er præget med tallet "93" og den anden side af tabletten er præget med tallet "7239". 
One side of the tablet is debossed with the number “93” and the other side of the tablet is debossed with the number “7239”.
Ved ambulant blodtrykskontrol medførte kombinationen af 150 mg irbesartan og 12,5 mg hydrochlorthiazid, 1 gang dagligt, en vedvarende reduktion af blodtrykket over en 24 timers periode med en gennemsnitlig 24 timers placebo-korrigeret systolisk/diastolisk reduktion på 15,8/10,0 mm Hg. 
When assessed by ambulatory blood pressure monitoring, the combination 150 mg irbesartan and 12.5 mg hydrochlorothiazide once daily produced consistent reduction in blood pressure over the 24 hours period with mean 24-hour placebosubtracted systolic/diastolic reductions of 15.8/10.0 mmHg.
• i et 6 måneders toksicitetsstudie med irbesartan 90 mg/kg/dag, hydrochlorthiazid 90 mg/kg/dag, 
6 months toxicity study at irbesartan 90 mg/kg/day, hydrochlorothiazide 90 mg/kg/day, and irbesartan/hydrochlorothiazide 10/10 mg/kg/day.
Risikominimerende foranstaltninger 
Measures to mitigate the risk
Tag ikke medicin, der indeholder lithium, samtidig med at du tager Irbesartan/Hydrochlorthiazid Teva uden grundig vejledning fra lægen. 
Preparations containing lithium should not be taken with Irbesartan/Hydrochlorothiaizde Teva without close supervision by your doctor.
Den ene side af tabletten er præget med tallet "93" og den anden side af tabletten er præget med tallet "7238". 
One side of the tablet is debossed with the number “93" and the other side of the tablet is debossed with the number "7238".
Irbesartan omdannes i leveren ved konjugering som glucuronid og ved oxidation. 
Irbesartan is metabolised by the liver via glucuronide conjugation and oxidation.
Brug af Irbesartan/Hydrochlorthiazid Teva sammen med alkohol 
Irbesartan/Hydrochlorothiazide Teva with alcohol
58 % af de inkluderede patienter var mænd. 
The study recruited 58 % males.
Senest to år efter 
Within 2 years after Commission Decision.
Irbesartan/Hydrochlorthiazid Teva må ikke anvendes til patienter med alvorlig nyrefunktionsnedsættelse (kreatininclearance < 30 ml/min) (se pkt. 
Irbesartan/Hydrochlorothiazide Teva should not be used in patients with severe renal impairment (creatinine clearance < 30 ml/min) (see section 4.3).
4.4), hyperurikæmi, glukosuri, hyperglykæmi, stigning i kolesterol og triglycerider 
Electrolyte imbalance (including hypokalaemia and hyponatraemia, see section 4.4), hyperuricaemia, glycosuria, hyperglycaemia, increases in cholesterol and triglycerides
Der er ingen klinisk erfaring med Irbesartan/Hydrochlorthiazid Teva hos patienter med nedsat leverfunktion. 
There is no clinical experience with Irbesartan/Hydrochlorothiazide Teva in patients with hepatic impairment.
Den anden side af tabletten er præget med tallet "7469". 
The other side of the tablet debossed with the number "7469".
Ved hypotension lægges patienten i rygleje og salt- og væsketilskud administreres straks. 
If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly.
Din læge vil normalt anbefale, at du stopper med at tage Irbesartan/Hydrochlorthiazid Teva, inden du bliver gravid, eller så snart du ved, at du er gravid. 
Your doctor will normally advise you to stop taking Irbesartan/Hydrochlorothiazide Teva before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Irbesartan/Hydrochlorothiazide Teva.
Data fra kliniske studier har vist, at dobbelthæmning af renin-angiotensin-aldosteronsystemet (RAAS) gennem kombinationsbehandling med ACE-hæmmere, angiotensin II-receptorantagonister eller aliskiren er forbundet med en højere hyppighed af bivirkninger som hypotension, hyperkaliæmi og nedsat nyrefunktion (inklusive akut nyresvigt) sammenlignet med brug af et enkelt RAAS-virkende lægemiddel (se pkt. 
Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).
Irbesartan fjernes ikke ved hæmodialyse. 
Irbesartan is not removed by haemodialysis.
Hvis du har glemt at tage Irbesartan/Hydrochlorthiazid Teva 
If you forget to take Irbesartan/Hydrochlorothiazide Teva
Filmovertræk for styrken 300 mg/25 mg: 
300 mg/25 mg strength:
Irbesartan/Hydrochlorthiazid Teva er ikke indiceret til patienter med svært nedsat leverfunktion. 
Irbesartan/Hydrochlorothiazide Teva is not indicated in patients with severe hepatic impairment.
Virkningen af kombinationen af irbesartan/hydrochlorthiazid afhænger ikke af alder eller køn. 
There is no difference in response to irbesartan/hydrochlorothiazide, regardless of age or gender.
For risikopatienter anbefales tilstrækkelig monitorering af serum-kalium (se pkt. 
Adequate monitoring of serum potassium in patients at risk is recommended (see section
• Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg kan gives til patienter, hvis blodtryk ikke kan reguleres tilstrækkeligt med hydrochlorthiazid eller irbesartan 150 mg alene; 
• Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;
Pakningsstørrelse a 28 filmovertrukne tabletter i enhedsdosisblistre. 
Pack size of 28 film-coated tablets in non-perforated calendar blisters.
Filmovertræk for styrkerne 150 mg/12,5 mg og 300 mg/12,5 mg: Hypromellose 
150 mg/12.5 mg and 300 mg/12.5 mg strengths: Hypromellose
Kontakt lægen, før du tager Irbesartan/Hydrochlorthiazid Teva, hvis du oplever følgende: 
Talk to your doctor before taking Irbesartan/Hydrochlorothiazide Teva and if any of the following apply to you:
Brystsmerter 
Cardiac arrhythmias
Kombinationen af en ACE-hæmmer og en angiotensin II-receptorantagonist er undersøgt i to store randomiserede, kontrollerede studier (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) og VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)). 
Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.
Ved meget høje doser (≥ 500 mg/kg/dag) inducerede irbesartan degenerative forandringer i nyrerne (fx interstitiel nefritis, tubulær udvidelse, basofile tubuli, øgede plasmakoncentrationer af carbamid og kreatinin) hos rotter og makakaber. 
At very high doses (≥ 500 mg/kg/day) degenerative changes in the kidneys (such as interstitial nephritis, tubular distention, basophilic tubules, increased plasma concentrations of urea and creatinine) were induced by irbesartan in the rat and the macaque and are considered secondary to the hypotensive effects of the medicinal product which led to decreased renal perfusion.
Hvide, uigennemsigtige PVC-PVdC - aluminiumblistere: Må ikke opbevares ved temperaturer over 30 °C. 
White opaque PVC-PVdC - Aluminium blisters: Do not store above 30°C.
Irbesartan/hydrochlorthiazid 
Irbesartan/hydrochlorothiazide
For at minimere risikoen for hudkræft bør patienterne rådes til at træffe forebyggende foranstaltninger som f.eks. at begrænse eksponeringen for sollys og UV-stråler og, ved eksponering, at sørge for tilstrækkelig beskyttelse. 
Possible preventive measures such as limited exposure to sunlight and UV rays and, in case of exposure, adequate protection should be advised to the patients in order to minimize the risk of skin cancer.
Thiazidinduceret hypokaliæmi eller hypomagnesiæmi øger forekomsten af digitalisinducerede kardielle arytmier (se pkt. 
Thiazide induced hypokalaemia or hypomagnaesemia favour the onset of digitalis-induced cardiac arrhythmias (see section 4.4);
Bivirkninger, hvor hyppigheden ikke er kendt: hovedpine, ringen for ørerne, hoste, smagsforstyrrelser, forstoppelse, led- og muskelsmerter, leversygdom og nedsat nyrefunktion, øget mængde af kalium i blodet og allergiske reaktioner, såsom udslæt, nældefeber, opsvulmet ansigt, læber, mund, tunge og hals. 
Undesirable effects where the frequency is not known are: headache, ringing in the ears, cough, taste disturbance, indigestion, pain in joints and muscles, liver function abnormal and impaired kidney function, increased level of potassium in your blood and allergic reactions such as rash, hives, swelling of the face, lips, mouth, tongue or throat.
I to epidemiologiske studier baseret på det danske Cancerregister er der observeret øget risiko for nonmelanom hudkræft (basalcellekarcinom og pladecellekarcinom) ved en stigende kumulativ dosis af hydrochlorthiazid. 
An increased risk of non-melanoma skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] with increasing cumulative dose of hydrochlorothiazide (HCTZ) exposure has been observed in two epidemiological studies based on the Danish National Cancer Registry.
Irbesartan/Hydrochlorthiazid Teva er tilgængelige i pakningsstørrelser med 7, 14, 15, 20, 28, 30, 56, 60, 84, 90, 98 og 100 filmovertrukne i ikke perforerede blisterpakninger; pakningsstørrelser med 50x1 filmovertrukken tablet i enhedsblisterpakninger og pakningsstørrelse med 28 filmovertrukne tabletter i ikke perforerede kalenderblisterpakninger. 
Irbesartan/Hydrochlorothiazide Teva is available in pack sizes of 7, 14, 15, 20, 28, 30, 56, 60, 84, 90, 98 and 100 film-coated tablets in non-perforated blisters; pack sizes of 50 x 1 film coated tablet in unit dose blisters and pack size of 28 film-coated tablets in non-perforated calendar blisters.
Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukne tabletter EU/1/09/583/049-072 
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets EU/1/09/583/049-072
Indigotin (Indigocarmin) Sort jernoxid 
Indigotine (Indigo carmine aluminium lake FD&C blue #2) Iron Oxide Black
Faldet i SeSBT/SeDBT ved 5 uger var henholdsvis 30,8/24,0 mm Hg og 21,1/19,3 mm Hg for irbesartan/hydrochlorthiazid og irbesartan (p < 0,0001). 
The mean baseline blood pressure was approximately 172/113 mmHg in each treatment group and decreases of SeSBP/SeDBP at five weeks were 30.8/24.0 mmHg and 21.1/19.3 mmHg for irbesartan/hydrochlorothiazide and irbesartan, respectively (p < 0.0001).
Dosering 1 gang dagligt med 150 mg irbesartan og 12,5 mg hydrochlorthiazid gav en systolisk/diastolisk gennemsnitlig placebojusteret blodtryksreduktion ved laveste måling (24 timer efter dosis) på 12,9/6,9 mm Hg hos patienter med let til moderat hypertension. 
Once daily dosing with 150 mg irbesartan and 12.5 mg hydrochlorothiazide gave systolic/diastolic mean placebo-adjusted blood pressure reductions at trough (24 hours post-dosing) of 12.9/6.9 mmHg in patients with mild-to-moderate hypertension.
Dog skal denne faste dosiskombination gives med forsigtighed til patienter med mild til moderat nedsat nyrefunktion (kreatininclearance ≥ 30 ml/min, men < 60 ml/min). 
However, in patients with mild to moderate renal impairment (creatinine clearance ≥ 30 ml/min but < 60 ml/min) this fixed dose combination should be administered with caution.
Non-steroide antiinflammatoriske lægemidler Administration af et non-steroidt antiinflammatorisk lægemiddel kan reducere den diuretiske, 
The administration of a non-steroidal anti-inflammatory drug may reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics in some patients;
Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg 
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg
Den anden side af tabletten er præget med tallet "7238". 
The other side of the tablet debossed with the number "7238".
Stort forbrug af hydrochlorthiazid (≥ 50.000 mg kumulativt) var forbundet med en justeret OR-værdi på 1,29 (95 %KI: 1,23-1,35) for basalcellekarcinom og på 3,98 (95 %-KI: 3,68-4,31) for pladecellekarcinom. 
(95% CI: 1.23-1.35) for BCC and 3.98 (95% CI: 3.68-4.31) for SCC.
Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukne tabletter EU/1/09/583/025-048 
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets EU/1/09/583/025-048
Derfor frarådes brug af Irbesartan/Hydrochlorthiazid Teva. 
Therefore, the use of Irbesartan/Hydrochlorothiazide Teva is not recommended.
Halveringstiden for hydrochlorthiazid forlænges til 21 timer hos patienter med kreatininclearance < 20 ml/min. 
In patients with creatinine clearance < 20 ml/min, the elimination half-life of hydrochlorothiazide was reported to increase to 21 hours.
Dosisjustering af Irbesartan/Hydrochlorthiazid Teva til patienter med mild eller moderat leverfunktionsnedsættelse er ikke nødvendig (se pkt. 
No dosage adjustment of Irbesartan/Hydrochlorothiazide Teva is necessary in patients with mild to moderate hepatic impairment (see section 4.3).
Non-melanom hudkræft: Tilgængelige data fra epidemiologiske studier viser en kumulativ dosisafhængig forbindelse mellem hydrochlorthiazid og non-melanom hudkræft. 
Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dosedependent association between HCTZ and NMSC has been observed.
Artralgi, myalgi 
Swelling extremity Arthralgia, myalgia
Luftveje, thorax og mediastinum 
Respiratory, thoracic and mediastinal disorders:
Anvendelse af Irbesartan/Hydrochlorothiazide Teva i ammeperioden frarådes. 
The use of Irbesartan/Hydrochlorothiazide Teva during breast feeding is not recommended.
Virkningen af pressoraminer kan nedsættes, men ikke tilstrækkeligt til at udelukke deres anvendelse; 
Pressor amines (e.g. noradrenaline) The effect of pressor amines may be decreased, but not sufficiently to preclude their use;
Forholdet mellem den laveste og den maksimale effekt var henholdsvis 68 % og 76 % for irbesartan/hydrochlorthiazid 150 mg /12,5 mg og irbesartan/hydrochlorthiazid 300 mg /12,5 mg, når effekten blev målt med blodtryksmanchet ved kontrolbesøg. 
The trough to peak effects measured by cuff during office visits were 68 % and 76 % for irbesartan/hydrochlorothiazide 150 mg/12.5 mg and irbesartan/hydrochlorothiazide 300 mg/12.5 mg, respectively.
Elektrolytforstyrrelser 
Electrolyte imbalance
• Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg kan gives til patienter, der er utilstrækkeligt regulerede med Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg. 
• Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg may be administered in patients insufficiently controlled by Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg.
Ortostatisk svimmelhed 
Vascular disorders:
Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukne tabletter EU/1/09/583/001-024 
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets EU/1/09/583/001-024
• Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg kan gives til patienter, der er utilstrækkeligt regulerede med irbesartan 300 mg eller med Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg. 
• Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg.
Yderligere information om irbesartaninteraktioner Irbesartans farmakokinetik er i kliniske forsøg ikke blevet påvirket af hydrochlorthiazid. 
In clinical studies, the pharmacokinetic of irbesartan is not affected by hydrochlorothiazide.
Den anden side af tabletten er præget med tallet "7239". 
The other side of the tablet debossed with the number "7239".
Pakningsstørrelser og yderligere oplysninger Irbesartan/hydrochlorthiazid Teva indeholder: 
Contents of the pack and other information What Irbesartan/Hydrochlorothiazide Teva contains
Lægen vil sandsynligvis starte behandling med Irbesartan/Hydrochlorthiazid Teva, hvis den tidligere behandling for forhøjet blodtryk ikke har haft tilstrækkelig effekt. 
Irbesartan/Hydrochlorothiazide Teva will usually be prescribed by your doctor when your previous treatment for high blood pressure did not provide appropriate blood pressure reduction.
Nervesystemet 
Nervous system disorders:
Kombination af irbesartan/hydrochlorthiazid 
Irbesartan/hydrochlorothiazide combination
Hver filmovertrukket tablet indeholder 300 mg irbesartan og 25 mg hydrochlorthiazid 
Each film-coated tablet contains 300 mg irbesartan and 25 mg hydrochlorothiazide
Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg filmovertrukne tabletter Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg filmovertrukne tabletter Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukne tabletter 
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets
Irbesartan/Hydrochlorthiazid Teva 150 mg/12,5 mg 
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg
Patienter, der planlægger at blive gravide, bør skifte til anden antihypertensiv behandling hvor sikkerhedsprofilen for anvendelse under graviditet er veletableret, medmindre fortsat behandling med AIIRA'er skønnes nødvendig. 
Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.
Patienter, der planlægger at blive gravide, bør skifte til anden antihypertensiv behandling, hvor sikkerhedsprofilen for anvendelse under graviditet er veletableret, medmindre fortsat behandling med AIIRA skønnes nødvendig. 
Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.
Særlige patientgrupper 
Special Populations
FREMSTILLER(E) ANSVARLIG(E) FOR BATCHFRIGIVELSE 
MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE
Tabletovertræk for styrken 150 mg/12,5 mg: Hypromellose, titandioxid, polyethylenglycol 6000 (macrogol), polyethylenglycol 400 (macrogol), rød jernoxid, gul jernoxid og sort jernoxid. 
Tablet coating for 150 mg/12.5 mg strength: hypromellose, titanium dioxide, polyethylene glycol 6000 (macrogol), polyethylene glycol 400 (macrogol), iron oxide red, iron oxide yellow and iron oxide black.
Tillæg af 12,5 mg hydrochlorthiazid til 300 mg irbesartan 1 gang dagligt hos patienter, der ikke er tilstrækkeligt behandlede med 300 mg irbesartan alene, medførte yderligere placebo-korrigeret diastolisk blodtryksreduktion ved laveste måling (24 timer efter dosis) på 6,1 mm Hg. Kombinationen af 300 mg irbesartan og 12,5 mg hydrochlorthiazid medførte en total placebo-korrigeret systolisk/diastolisk reduktion på op til 13,6/11,5 mm Hg. 
The addition of 12.5 mg hydrochlorothiazide to 300 mg irbesartan once daily in patients not adequately controlled on 300 mg irbesartan alone resulted in further placebo-corrected diastolic blood pressure reductions at trough (24 hours post-dosing) of 6.1 mmHg.
Lithium Kombination af lithium og Irbesartan/Hydrochlorthiazid Teva frarådes (se pkt. 
Lithium The combination of lithium and Irbesartan/Hydrochlorothiazide Teva is not recommended (see section 4.5).
Tabletovertræk for styrken 300 mg/25 mg: Hypromellose, titandioxid, polyethylenglycol 6000 (macrogol), polyethylenglycol 400 (macrogol), rød jernoxid, Indigotin (Indigocarmin) og sort jernoxid. 
Tablet coating for 300 mg/25 mg strength: hypromellose, titanium dioxide, polyethylene glycol 6000 (macrogol), polyethylene glycol 400 (macrogol), iron oxide red, Indigotine (Indigo carmine aluminium lake FD&C blue #2) and iron oxide black.
Et randomiseret, dobbeltblindt, aktivt kontrolleret, parallelt multicenterforsøg af 8 ugers varighed har evalueret effekten og sikkerheden af irbesartan/hydrochlorthiazid som initial behandling ved svær hypertension (defineret som SeDBT ≥ 110 mm Hg). 
Efficacy and safety of irbesartan/hydrochlorothiazide as initial therapy for severe hypertension (defined as SeDBP ≥ 110 mmHg) was evaluated in a multicentre, randomised, double-blind, active-controlled, 8-week, parallel-arm study.
Samtidig administration af irbesartan ændrer det kalium-tab, der er forbundet med disse diuretika, formodentligt ved at blokere renin-angiotensin-aldosteronsystemet. 
Presumably through blockade of the renin-angiotensin-aldosterone system, co-administration of irbesartan tends to reverse the potassium loss associated with these diuretics.
Derfor frarådes kombination af lithium og Irbesartan/Hydrochlorthiazid Teva (se pkt. 
Therefore, the combination of lithium and Irbesartan/Hydrochlorothiazide Teva is not recommended (see section 4.4).
Non-melanom hudkræft: Tilgængelige data fra epidemiologiske studier viser en kumulativ dosisafhængig forbindelse mellem hydrochlorthiazid og non-melanom hudkræft (se også pkt. 
Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dosedependent association between HCTZ and NMSC has been observed (see also sections 4.4 and 5.1).
Brug af anden medicin sammen med Irbesartan/Hydrochlorthiazid Teva 
Other medicines and Irbesartan/Hydrochlorothiazide Teva
Tabletovertræk for styrken 300 mg/12,5 mg: Hypromellose, titandioxid, polyethylenglycol 6000 (macrogol), polyethylenglycol 400 (macrogol), rød jernoxid, gul jernoxid og sort jernoxid. 
Tablet coating for 300 mg/12.5 mg strength: hypromellose, titanium dioxide, polyethylene glycol 6000 (macrogol), polyethylene glycol 400 (macrogol), iron oxide red, iron oxide yellow and iron oxide black.
Irbesartan/Hydrochlorthiazid Teva 300 mg/12,5 mg 
Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg
Der er dog rapporteret minimal eller ingen effekt ved en dosis på 12,5 mg, som findes i kombinationen af irbesartan og hydrochlorthiazid. 
Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy; however at the 12.5 mg dose contained in the irbesartan and hydrochlorothiazide combination, minimal or no effects were reported.
Hver filmovertrukket tablet indeholder 150 mg irbesartan og 12,5 mg hydrochlorthiazid 
Each film-coated tablet contains 150 mg irbesartan and 12.5 mg hydrochlorothiazide
Irbesartans farmakokinetiske parametre ændres ikke væsentligt hos patienter med mild/moderat cirrhose. 
In patients with mild to moderate cirrhosis, the pharmacokinetic parameters of irbesartan are not significantly altered.
Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukne tabletter irbesartan/hydrochlorthiazid 
Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets irbesartan/hydrochlorothiazide
Hver filmovertrukket tablet indeholder 300 mg irbesartan og 12,5 mg hydrochlorthiazid 
Each film-coated tablet contains 300 mg irbesartan and 12.5 mg hydrochlorothiazide
LISTE OVER HJÆLPESTOFFER LÆGEMIDDELFORM OG INDHOLD (PAKNINGSSTØRRELSE) 
PHARMACEUTICAL FORM AND CONTENTS
Hvis du drikker alkohol, mens du er i behandling med dette produkt, kan du opleve, at du bliver mere svimmel, især når du rejser dig op fra siddende stilling. 
Due to the hydrochlorothiazide contained in Irbesartan/Hydrochlorothiazide Teva, if you drink alcohol while on treatment with this medicine, you may have an increased feeling of dizziness on standing up, specially when getting up from a sitting position.
Administration Til oral brug. 
For oral use.
≥ 100 mg/kg/dag hos makakaber) en reduktion i røde blodlegemeparametre (erytrocytter, hæmoglobin, hæmatokrit). 
caused a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit).
Hydrochlorthiazids fotosensibiliserende virkning kan være en mulig mekanisme i forhold til non-melanom hudkræft. 
Photosensitizing actions of HCTZ could act as a possible mechanism for NMSC.
Sådan skal du tage Irbesartan/Hydrochlorthiazid Teva 
How to take Irbesartan/Hydrochlorothiazide Teva
Indlægsseddel: Information til brugeren Irbesartan/Hydrochlorthiazid Teva 300 mg/25 mg filmovertrukne tabletter irbesartan / hydrochlorthiazid 
Package leaflet: information for the patient Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets irbesartan / hydrochlorothiazide